Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tippett Ashley, Prasad Pragati V, Begier Elizabeth, Kim Sara S, Gibson Theda, Salazar Luis W, Taylor Meg, Reese Olivia, Ess Gabby, Choi Chris, Ciric Caroline, Taylor Elizabeth Grace, De Castro Khalel, Jadhao Samadhan, Sun HeYing, Hsiao Hui-Mien, Gupta Shadwal, Li Wensheng, Stephens Kathleen, Hubler Robin, Liu Qing, Swerdlow David, Gessner Bradford D, Uppal Sonal, Liang Caihua, Kalina Warren, Jodar Luis, Kamidani Satoshi, Yildirim Inci, Rouphael Nadine, Nelson Kristin N, Anderson Larry J, Rostad Christina A, Anderson Evan J
Аннотация
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory illness (ARI) in older adults and those with comorbidities. Understanding disease burden could guide prevention efforts.
METHODS: We performed active surveillance for RSV among adults aged ≥50 years hospitalized with ARI and adults of any age hospitalized with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) exacerbations from Georgia Health District 3 at 2 Atlanta hospitals during 2 respiratory seasons (2018-2019 and 2019-2020). All participants were tested for RSV using the BioFire Respiratory Panel (nasopharyngeal and oropharyngeal swabs); subsets also had serology and standard-of-care results. Annual population-based incidences of RSV-related hospitalizations were estimated by age strata and study group, adjusting for differences in sampling, diagnostic testing, and test sensitivity. Denominators for ARI incidence estimates were from the US Census. CHF and COPD denominators were limited to individuals with underlying CHF or COPD, respectively, as defined by NHANES data.
RESULTS: Of 3090 eligible patients, 1558 were included; 757 (48.6%) had ARI, 490 (31.4%) CHF exacerbation, and 311 (20.0%) COPD exacerbation. Overall, 92 (5.9%) participants tested positive for RSV. Based on data from 2 seasons, annual population-based incidences among adults aged ≥50 years were 74 per 100 000 (95% confidence interval [CI]: 73, 77) for laboratory-confirmed RSV-related ARI hospitalizations alone, and 58% higher when including all laboratory-confirmed RSV-related hospitalizations (ARI and CHF/COPD exacerbations): 117 per 100 000 (95% CI: 114, 123).
CONCLUSIONS: RSV was associated with a substantial burden of hospitalizations among adults aged ≥50 years, particularly when CHF and COPD exacerbations were included.
METHODS: We performed active surveillance for RSV among adults aged ≥50 years hospitalized with ARI and adults of any age hospitalized with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) exacerbations from Georgia Health District 3 at 2 Atlanta hospitals during 2 respiratory seasons (2018-2019 and 2019-2020). All participants were tested for RSV using the BioFire Respiratory Panel (nasopharyngeal and oropharyngeal swabs); subsets also had serology and standard-of-care results. Annual population-based incidences of RSV-related hospitalizations were estimated by age strata and study group, adjusting for differences in sampling, diagnostic testing, and test sensitivity. Denominators for ARI incidence estimates were from the US Census. CHF and COPD denominators were limited to individuals with underlying CHF or COPD, respectively, as defined by NHANES data.
RESULTS: Of 3090 eligible patients, 1558 were included; 757 (48.6%) had ARI, 490 (31.4%) CHF exacerbation, and 311 (20.0%) COPD exacerbation. Overall, 92 (5.9%) participants tested positive for RSV. Based on data from 2 seasons, annual population-based incidences among adults aged ≥50 years were 74 per 100 000 (95% confidence interval [CI]: 73, 77) for laboratory-confirmed RSV-related ARI hospitalizations alone, and 58% higher when including all laboratory-confirmed RSV-related hospitalizations (ARI and CHF/COPD exacerbations): 117 per 100 000 (95% CI: 114, 123).
CONCLUSIONS: RSV was associated with a substantial burden of hospitalizations among adults aged ≥50 years, particularly when CHF and COPD exacerbations were included.